VIR_logo_large.jpg
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
24 juin 2023 05h30 HE | Vir Biotechnology, Inc.
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in...
VIR_logo_large.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
07 juin 2023 02h13 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
05 juin 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to...
VIR_logo_large.jpg
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
17 mai 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19,...
VIR_logo_large.jpg
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
15 mai 2023 08h00 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer....
VIR_logo_large.jpg
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
11 mai 2023 08h30 HE | Vir Biotechnology, Inc.
– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
04 mai 2023 16h05 HE | Vir Biotechnology, Inc.
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
03 mai 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at...
VIR_logo_large.jpg
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
02 mai 2023 09h00 HE | Vir Biotechnology, Inc.
– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector – – Long-standing partnership...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head...